Guardant Health, Inc. (GH) Stock Analysis
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $83.90: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum.
Guardant Health is a precision oncology company offering liquid biopsy blood tests across all cancer care stages—Guardant360 CDx (advanced-stage therapy selection), Guardant Reveal (MRD detection), and Shield (FDA-approved colorectal cancer screening). Tests accounted for 94% of... Read more
Sell if holding. Engine safety override at $83.90: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.6/10, moderate confidence.
Passes 4/6 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProducttests94%10-K Item 1A: 'our tests, which accounted for 94%, 94% and 91% of our revenue in the years ended December 31, 2025, 2024 and 2023, respectively'
- HIGHCustomerthird-party commercial payers10-K Item 1A: 'We receive a substantial portion of our revenue from a limited number of third-party commercial payers'
- LOWCustomerMedicare10-K Item 1A: 'Revenue attributable to Medicare accounted for more than 10% of our total revenue in each of the years ended December 31, 2025, 2024 and 2023.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -42.4%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $83.90: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $77.91. Score 5.6/10, moderate confidence.
Take-profit target: $115.50 (+37.9% upside). Prior stop was $77.91. Stop-loss: $77.91.
Concentration risk — Product: tests (94.0%); Concentration risk — Customer: third-party commercial payers; Quality below floor (3.5 < 4.0).
Guardant Health, Inc. trades at a P/E of N/A (forward -119.6). TrendMatrix value score: 6.4/10. Verdict: Sell.
34 analysts cover GH with a consensus score of 4.3/5. Average price target: $128.
What does Guardant Health, Inc. do?Guardant Health is a precision oncology company offering liquid biopsy blood tests across all cancer care...
Guardant Health is a precision oncology company offering liquid biopsy blood tests across all cancer care stages—Guardant360 CDx (advanced-stage therapy selection), Guardant Reveal (MRD detection), and Shield (FDA-approved colorectal cancer screening). Tests accounted for 94% of 2025 revenue; the company remains unprofitable with a $416M net loss in 2025.